{"id":"NCT00963937","sponsor":"GlaxoSmithKline","briefTitle":"Study to Evaluate the Efficacy and Safety of Oral Sumatriptan for the Acute Treatment of Migraine in Children and Adolescents","officialTitle":"A Randomized, Multicenter, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Oral Sumatriptan for the Acute Treatment of Migraine in Children and Adolescents","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-09-28","primaryCompletion":"2010-12-01","completion":"2010-12-03","firstPosted":"2009-08-24","resultsPosted":"2011-08-26","lastUpdate":"2018-08-06"},"enrollment":178,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Migraine Disorders"],"interventions":[{"type":"DRUG","name":"Sumatriptan 25 mg","otherNames":[]},{"type":"DRUG","name":"Sumatriptan 50 mg","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Sumatriptan 25 mg","type":"ACTIVE_COMPARATOR"},{"label":"Sumatriptan 50 mg","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the efficacy and safety of a range of doses of oral sumatriptan for the acute treatment of migraine in children ages 10 to 17.","primaryOutcome":{"measure":"Percentage of Participants Who Reported Pain Relief at 120 Minutes Post-Treatment","timeFrame":"120 minutes post-treatment (Randomization through Final Visit [Week 6])","effectByArm":[{"arm":"Placebo","deltaMin":38.6,"sd":null},{"arm":"Sumatriptan Pooled","deltaMin":31.1,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.345"}]},"eligibility":{"minAge":"10 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":18,"exclusionCount":16},"locations":{"siteCount":16,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":70},"commonTop":["Chest discomfort","Somnolence","Blood creatine phosphokinase increased"]}}